Relevant bibliographies by topics / Elocalcitolo / Journal articles

Journal articles on the topic 'Elocalcitolo'

To see the other types of publications on this topic, follow the link: Elocalcitolo.
Author: Grafiati
Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 21 journal articles for your research on the topic 'Elocalcitolo.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Morelli, Annamaria, Roberta Squecco, Paola Failli, Sandra Filippi, Linda Vignozzi, Aravinda K. Chavalmane, Benedetta Fibbi, et al. "The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder." American Journal of Physiology-Cell Physiology 294, no. 5 (May 2008): C1206—C1214. http://dx.doi.org/10.1152/ajpcell.90634.2007.

Full text
Abstract:
Human bladder contraction mainly depends on Ca2+ influx via L-type voltage-gated Ca2+ channels and on RhoA/Rho kinase contractile signaling, which is upregulated in overactive bladder (OAB). Elocalcitol is a vitamin D receptor agonist inhibiting RhoA/Rho kinase signaling in rat and human bladder. Since in the normal bladder from Sprague-Dawley rats elocalcitol treatment delayed the carbachol-induced contraction without changing maximal responsiveness and increased sensitivity to the L-type Ca2+ channel antagonist isradipine, we investigated whether elocalcitol upregulated L-type Ca2+ channels in human bladder smooth muscle cells (hBCs). In hBCs, elocalcitol induced a rapid increase in intracellular [Ca2+], which was abrogated by the L-type Ca2+ channel antagonist verapamil. Moreover, hBCs exhibited L-type voltage-activated Ca2+ currents ( ICa), which were selectively blocked by isradipine and verapamil and enhanced by the selective L-type agonist BAY K 8644. Addition of elocalcitol (10−7 M) increased L-type ICa size and specific conductance by inducing faster activation and inactivation kinetics than control and BAY K 8644, while determining a significant negative shift of the activation and inactivation curves, comparable to BAY K 8644. These effects were strengthened in long-term treated hBCs with elocalcitol (10−8 M, 48 h), which also showed increased mRNA and protein expression of pore-forming L-type α1C-subunit. In the bladder from Sprague-Dawley rats, BAY K 8644 induced a dose-dependent increase in tension, which was significantly enhanced by elocalcitol treatment (30 μg·kg−1·day−1, 2 wk). In conclusion, elocalcitol upregulated Ca2+ entry through L-type Ca2+ channels in hBCs, thus balancing its inhibitory effect on RhoA/Rho kinase signaling and suggesting its possible efficacy for the modulation of bladder contractile mechanisms.
APA, Harvard, Vancouver, ISO, and other styles
2

Borgogni, E., E. Sarchielli, M. Sottili, V. Santarlasci, L. Cosmi, S. Gelmini, A. Lombardi, et al. "Elocalcitol Inhibits Inflammatory Responses in Human Thyroid Cells and T Cells." Endocrinology 149, no. 7 (March 27, 2008): 3626–34. http://dx.doi.org/10.1210/en.2008-0078.

Full text
Abstract:
T-helper 1 (Th1) cell-mediated inflammatory responses predominate in the early pathogenesis of Graves’ disease (GD), whereas Th2 cell-mediated immunity may play a role in later stages. The chemokine CXCL10 and its receptor CXCR3 are expressed in most thyroid glands of early GD patients. Circulating CXCL10 levels inversely correlate with disease duration; CXCL10 maximal expression also correlates with interferon (IFN)γ levels in recent GD onset. Methimazole (MMI) reduces CXCL10 secretion by isolated thyrocytes, decreases serum CXCL10 levels, and promotes a transition from Th1 to Th2 dominance in patients in GD active phase. Vitamin D receptor agonists exhibit antiinflammatory properties and promote tolerance induction. We investigated the effects and the mechanism of action of a nonhypercalcemic vitamin D receptor agonist, elocalcitol (BXL-628), compared with MMI on CXCL10 secretion induced by proinflammatory cytokines. Furthermore, we studied the effects of both drugs on Th1, Th17, and Th2 cytokine secretion in CD4+ T cells. ELISA, cytometry, immunocytochemistry, Western blot, and quantitative real-time PCR were used for protein and gene analysis. In human thyrocytes, elocalcitol inhibited IFNγ and TNFα-induced CXCL10 protein secretion more potently than MMI. Elocalcitol impaired both cytokine intracellular pathways, whereas MMI was effective only on the IFNγ pathway. In CD4+ T cells, elocalcitol decreased Th1- and Th17-type cytokines, and promoted Th2-type cytokine secretion. Elocalcitol and MMI inhibited Th1 cytokine-mediated responses in thyrocytes and CD4+ T cells. In addition, elocalcitol promoted a shift toward a Th2 response. In conclusion, elocalcitol could represent a novel pharmacological tool in the treatment of autoimmune thyroid diseases.
APA, Harvard, Vancouver, ISO, and other styles
3

Revill, P., N. Serradell, and J. Bolós. "Elocalcitol." Drugs of the Future 31, no. 12 (2006): 1042. http://dx.doi.org/10.1358/dof.2006.031.12.1060203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Elocalcitol beneficial for benign prostatic hyperplasia." Inpharma Weekly &NA;, no. 1610 (October 2007): 8. http://dx.doi.org/10.2165/00128413-200716100-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "BXL 628* [Elocalcitol] is effective in the treatment of overactive bladder,." Inpharma Weekly &NA;, no. 1538 (May 2006): 6. http://dx.doi.org/10.2165/00128413-200615380-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Streng, T., K. E. Andersson, P. Hedlund, C. Gratzke, E. Baroni, D. D'Ambrosio, and F. Benigni. "548 ELOCALCITOL IMPROVES EFFECTS BY TOLTERODINE IN RATS WITH PARTIAL URETHRAL OBSTRUCTION." European Urology Supplements 10, no. 2 (March 2011): 181–82. http://dx.doi.org/10.1016/s1569-9056(11)60539-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Streng, Tomi, Karl-Erik Andersson, Petter Hedlund, Christian Gratzke, Enrico Baroni, Daniele D'Ambrosio, and Fabio Benigni. "Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction." BJU International 110, no. 2b (January 30, 2012): E125—E131. http://dx.doi.org/10.1111/j.1464-410x.2011.10838.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tiwari, Atul. "Elocalcitol (BXL-628): a novel, investigational therapy for the therapeutic management of benign prostatic hyperplasia." Expert Opinion on Investigational Drugs 17, no. 5 (April 30, 2008): 819–24. http://dx.doi.org/10.1517/13543784.17.5.819.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Adorini, Luciano, Giuseppe Penna, Susana Amuchastegui, Chiara Cossetti, Francesca Aquilano, Roberto Mariani, Benedetta Fibbi, et al. "Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol)." Journal of Steroid Biochemistry and Molecular Biology 103, no. 3-5 (March 2007): 689–93. http://dx.doi.org/10.1016/j.jsbmb.2006.12.065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Montorsi, Francesco, and Enrico Colli. "ELOCALCITOL IN THE TREATMENT OF BPH: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED PHASE IIB CLINICAL TRIAL." Journal of Urology 179, no. 4S (April 2008): 700–701. http://dx.doi.org/10.1016/s0022-5347(08)62043-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Penna, Giuseppe, Susana Amuchastegui, Chiara Cossetti, Francesca Aquilano, Roberto Mariani, Francesca Sanvito, Claudio Doglioni, and Luciano Adorini. "Treatment of Experimental Autoimmune Prostatitis in Nonobese Diabetic Mice by the Vitamin D Receptor Agonist Elocalcitol." Journal of Immunology 177, no. 12 (December 1, 2006): 8504–11. http://dx.doi.org/10.4049/jimmunol.177.12.8504.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Antinozzi, Cristina, Clarissa Corinaldesi, Carla Giordano, Annalinda Pisano, Bruna Cerbelli, Silvia Migliaccio, Luigi Di Luigi, et al. "Potential role for the VDR agonist elocalcitol in metabolic control: Evidences in human skeletal muscle cells." Journal of Steroid Biochemistry and Molecular Biology 167 (March 2017): 169–81. http://dx.doi.org/10.1016/j.jsbmb.2016.12.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Fibbi, B., A. Morelli, M. Marini, X. H. Zhang, R. Mancina, L. Vignozzi, S. Filippi, et al. "Atorvastatin But Not Elocalcitol Increases Sildenafil Responsiveness in Spontaneously Hypertensive Rats by Regulating the RhoA/ROCK Pathway." Journal of Andrology 29, no. 1 (August 15, 2007): 70–84. http://dx.doi.org/10.2164/jandrol.107.003152.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Morelli, A., R. Squecco, F. Francini, P. Failli, S. Filippi, A. Chavalmane, B. Fibbi, et al. "UPREGULATION OF L-TYPE CA2+ CHANNEL ACTIVITY BY THE VDR AGONIST ELOCALCITOL IN HUMAN AND RAT BLADDER." European Urology Supplements 7, no. 3 (March 2008): 266. http://dx.doi.org/10.1016/s1569-9056(08)60780-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Mariani, M., P. Vigano, D. Gentilini, B. Camisa, E. Caporizzo, P. Di Lucia, A. Monno, M. Candiani, E. Somigliana, and P. Panina-Bordignon. "The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation." Human Reproduction 27, no. 7 (May 15, 2012): 2010–19. http://dx.doi.org/10.1093/humrep/des150.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Fibbi, Benedetta, Pietro Di Lucia, annamaria morelli, Sandra Filippi, Aravinda K. Chavalmane, Margherita Mariani, Linda Vignozzi, et al. "THE VDR AGONIST ELOCALCITOL REVERTS THE BENIGN PROSTATIC HYPERPLASIA (BPH)-ASSOCIATED INFLAMMATORY RESPONSE IN HUMAN URETHRAL SMOOTH MUSCLE CELLS." Journal of Urology 181, no. 4S (April 2009): 81. http://dx.doi.org/10.1016/s0022-5347(09)60233-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Maggi, M., C. Crescioli, A. Morelli, E. Colli, and L. Adorini. "Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol)." Journal of Endocrinological Investigation 29, no. 7 (July 2006): 665–74. http://dx.doi.org/10.1007/bf03344169.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Antinozzi, C., F. Marampon, P. Sgrò, V. Tombolini, A. Lenzi, C. Crescioli, and L. Di Luigi. "Comparative study of testosterone and vitamin D analogue, elocalcitol, on insulin-controlled signal transduction pathway regulation in human skeletal muscle cells." Journal of Endocrinological Investigation 42, no. 8 (January 1, 2019): 897–907. http://dx.doi.org/10.1007/s40618-018-0998-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Fibbi, B., P. Di Lucia, A. Morelli, A. Chavalmane, M. Mariani, S. Filippi, L. Vignozzi, et al. "350 THE VDR AGONIST ELOCALCITOL REVERTS THE BENIGN PROSTATIC HYPERPLASIA (BPH)-ASSOCIATED INFLAMMATORY RESPONSE IN AN IN VITRO MODEL OF HUMAN URETHRAL SMOTH MUSCLE CELLS." European Urology Supplements 8, no. 4 (March 2009): 208. http://dx.doi.org/10.1016/s1569-9056(09)60353-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Digesu, G. Alessandro, Elena Verdi, Linda Cardozo, Lorenza Olivieri, Vik Khullar, and Enrico Colli. "Phase IIb, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Determine Effects of Elocalcitol in Women With Overactive Bladder and Idiopathic Detrusor Overactivity." Urology 80, no. 1 (July 2012): 48–54. http://dx.doi.org/10.1016/j.urology.2012.03.035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Penna, Giuseppe, Benedetta Fibbi, Susana Amuchastegui, Elisa Corsiero, Gilles Laverny, Enrico Silvestrini, Aravinda Chavalmane, et al. "The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kB pathways." Prostate 69, no. 5 (December 23, 2008): 480–93. http://dx.doi.org/10.1002/pros.20896.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography